Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):: US0197701065
LEI:
Country:: United States of America
Address:: 210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://allogene.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Nuvation Bio Inc. A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.	United States of America	NUVB
Nxera Pharma Co., Ltd. Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.	Japan	4565
ObsEva SA Developed novel therapeutics for women's reproductive health and pregnancy.	Switzerland	OBSN
OCULAR THERAPEUTIX, INC Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.	United States of America	OCUL
Oculis Holding AG Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.	United States of America	OCS
ODI Pharma AB Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.	Sweden	ODI
Olema Pharmaceuticals, Inc. A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.	United States of America	OLMA
OliX Pharmaceuticals, Inc. Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.	South Korea	226950
OMEROS CORP Develops first-in-class therapeutics for challenging diseases with unmet medical needs.	United States of America	OMER
ONCODESIGN Developing precision oncology solutions for resistant and metastatic cancers.	France	ALONC